Drug Origin Transparency Act of 2026

Doris O. Matsui

Democrat · CA · Representative

Source: Congress.gov · FEC

• Ashley Hinson (R-IA-2)Original· 2026-04-16
• Dan Crenshaw (R-TX-2)Original· 2026-04-16
• Kim Schrier (D-WA-8)Original· 2026-04-16

Referred to the House Committee on Energy and Commerce.

2026-04-16

Source: Congress.gov

The bill would require drug manufacturers to provide more detailed information about how much medication they're producing and distributing, giving the government better visibility into drug supply chains and potential shortages. This would help federal health agencies track whether there are enough medicines available and identify problems before they become widespread supply issues. The changes would primarily affect pharmaceutical companies and the FDA, which oversees drug safety and availability.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 8339 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 8339 To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES April 16, 2026 Ms. Matsui (for herself, Mr. Crenshaw, Ms. Schrier, and Mrs. Hinson) introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Drug Origin Transparency Act of 2026''. SEC. 2. ENHANCED DRUG MANUFACTURING AMOUNT INFORMATION REPORTING. (a) In General.--Section 510(j)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360(j)(3)) is amended-- (1) in subparagraph (A), by adding ``or (2)'' after ``paragraph (1)''; and (2) by adding at the end the following: ``(C) Each report submitted pursuant to subparagraph (A) with respect to a drug shall-- ``(i) include additional information as may be specified by the Secretary in regulation or guidance regarding the supply chain for such drug, such as-- ``(I) the identity of the respective suppliers of each active pharmaceutical ingredient, active pharmaceutical ingredient intermediate, and in-process material used in such manufacture, preparation, propagation, compounding, or processing of the drug; and ``(II) the respective amounts of such drug that were manufactured, prepared, propagated, compounded, or processed using an active pharmaceutical ingredient, active pharmaceutical ingredient intermediate, and in- process material from each such identified supplier; and ``(ii) be submitted more frequently than annually, in accordance with a reporting schedule as may be specified by the Secretary in such regulation or guidance, but not more frequently than 4 times per year. ``(D) Any additional information specified in regulation or guidance pursuant to subparagraph (C) shall be a required element of reports under this paragraph not earlier than 6 months after the date on which such regulation or guidance is issued in final form (and in no event shall the absence of any regulation or guidance issued under subparagraph (C) affect the requirement to report as described in subparagraph (A)).''. (b) Conforming Amendment.--Section 510(j)(3)(B) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 510(j)(3)(B)) is amended by striking ``subparagraph (A)'' and inserting ``this paragraph''. SEC. 3. REQUIRE DRUG LABELING TO INCLUDE ORIGINAL MANUFACTURER AND SUPPLY CHAIN INFORMATION. Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352) is amended-- (1) in paragraph (b)-- (A) by striking ``(b) If in a package'' and inserting ``(b)(1) If in a package''; (B) by striking ``a label containing (1) the name and place'' and inserting ``a label containing-- ``(A) the name and place''; (C) by striking ``or distributor; and (2) an accurate statement'' and inserting ``or distributor; and ``(B) an accurate statement''; (D) by striking ``under clause (2) of this paragraph'' and inserting ``under this clause''; and (E) by inserting at the end the following: ``(2)(A) Subject to clause (C), if it is a drug, including an active pharmaceutical ingredient, unless it bears a label containing the name and place of business, and unique facility identifier of the original manufacturer of such drug or active pharmaceutical ingredient, except that the Secretary may provide, by regulation, for reasonable variations in the implementation of such labeling requirements. ``(B) Subject to clause (C), if it is a drug that is an active pharmaceutical ingredient, unless…

any accompanying certificate of analysis contains the name and place of business, and unique facility identifier of the original manufacturer of the active pharmaceutical ingredient. ``(C) The Secretary may provide, by regulation, for reasonable variations in the implementation of labeling requirements specified in this subparagraph.''; and (2) by inserting after paragraph (c) the following: ``(d)(1) Subject to subparagraph (2), if it is a drug, including an active pharmaceutical ingredient, unless it bears labeling containing the name and place of business of-- ``(A) the original manufacturer of each active pharmaceutical ingredient; ``(B) each manufacturer, if different from the original manufacturer; and ``(C) the packer or distributor, if any. ``(2) The Secretary may provide, by regulation, for reasonable variations or an alternative placement for the labeling requirements specified in subparagraph (1), including by electronic means.''. <all>

• HR8936Digital Opportunity Foundation Act of 2026
  Referred to Committee · 2026-05-20
• HR8487Ensuring Excellence in Mental Health Act
  Referred to Committee · 2026-04-23
• HRES1208Expressing support for honoring Earth Day, and for other purposes.
  Referred to Committee · 2026-04-22
• HR5201Kari's Law Reporting Act
  Passed House · 2026-04-22